Jump to content

What can I do with Mi Quirónsalud?
What can I do with Mi Quirónsalud?

imagen icono documento

Quick access to Quirónsalud laboratory test results and other documents

Quick access to Quirónsalud laboratory test results and other documents

To access test results, you must previously have been notified via email or test message.

imagen icono documento

Quick access to Quirónsalud laboratory test results and other documents

Quick access to Quirónsalud laboratory test results and other documents

To access test results, you must previously have been notified via email or test message.

Complete field

/ /

Complete field

Incorrect date entered

Complete field

I hereby declare that I hold custody rights over the minor whose medical records I am accessing at this time. Should I lose my rights of custody or guardianship for any reason, I endeavor to inform the hospital to this effect without delay.

You must accept the conditions

Quirónsalud with the support of the UCAM works in the investigation of personalized treatments in the fight against cancer

Vaccines, gene reading and multidisciplinary approach improve results and increase survival by offering an alternative to conventional methods

The Hospital Quirónsalud Torrevieja has launched a Clean Room designed under the international criteria of quality GMP (Good Manufacturing Practices) and intended for the development of advanced therapy drugs, such as vaccines with dendritic cells. The medical team of the Oncology Platform of the Hospital Quirónsalud Torrevieja, which is part of the Chair of Multidisciplinary Oncology of the UCAME This link will open in a new window and directs Dr. Antonio Brugarolas, has started the production of dendritic cells obtained from the patient's own blood, obtaining positive results in the treatment of metastatic prostate cancer. "In addition to working on this cancer, the White Room roadmap envisages the involvement in obtaining vaccines for the treatment of patients with melanoma and breast cancer," explains Dr. Juan José Mata, specialist in Immunology Hospital Quirónsalud Torrevieja, who explains that this vaccine will cause in vivo the activation and proliferation of tumor-specific effector T lymphocytes, which will recognize and eliminate cancer cells that express prostatic acid phosphatase.

Cells with a single nucleus (mononuclear), which are lymphocytes and monocytes, are selected from the patient's blood. Subsequently, by incubation of these mononuclear cells with different stimulatory molecules, a culture of dendritic cells is obtained. In the final phases, the dendritic cells are incubated with prostatic acid phosphatase to obtain specific dendritic cells of this protein that will finally be infused to the same patient. This vaccine will cause in vivo the activation and proliferation of tumor-specific effector T lymphocytes, which will recognize and eliminate cancer cells that express prostatic acid phosphatase.

New technology based on the reading of genes

Siguiendo con la línea de trabajo sobre tratamientos personalizados para la lucha contra el cáncer, el Hospital Quirónsalud Torrevieja pone en marcha un secuenciador de nueva generación, `Next Generation Sequencing´, para conocer el comportamiento del tumor a partir de ADN y ARN en pacientes que son resistentes a la quimioterapia convencional. "Podremos mirar en todos los tumores si hay alteraciones genéticas del ADN. En la actualidad un 20% de los pacientes estudiados presentan un ADN mutado y tratable de acuerdo a esa mutación. A medida que salgan nuevos fármacos para las diferentes mutaciones, se irán ampliando estas cifras", destaca el Dr. Brugarolas. Además, explica que no solo tienen como objetivo detectar las mutaciones que son tratables para administrar el tratamiento adecuado, sino también conocer la forma de reaccionar la célula a estas mutaciones. Podemos visualizar como se adapta la célula y predecir el tratamiento de quimioterapia más adecuado a cada tumor".

La nueva técnica implica sólamente una biopsia para el paciente, y en dos semanas se obtienen resultados. Además, permite elegir tratamientos según los costes, los efectos secundarios, la forma de administración y las preferencias del paciente. Hay medicamentos más caros y más baratos, hay tratamientos orales o intravenosos, en algunos hay caída del pelo y en otros no. Es decir, se puede personalizar la selección de los fármacos, entre los que son sensibles, descartando los menos eficaces. El Dr. Brugarolas, comenta que esta técnica tiene que seguir perfeccionándose porque todavía hay dificultades, a veces porque no se puede acceder directamente al tumor sin cirugía, otras porque las células seleccionadas están muertas. Se estudian en torno a 600 genes con una sola prueba y se puede predecir cuáles son los mejores fármacos para combatir ese tipo de cáncer. La predicción basada en el estudio de los genes, proporciona mejor tasa de respuesta que la que se daría con el uso convencional de quimioterapia. Además, añade el doctor que "mediante el análisis del RNA se puede predecir en un 70% la respuesta del paciente al tratamiento de quimioterapia".


A high resolution multidisciplinary conception

The oncology platform of Hospital Quirónsalud Torrevieja is integrated by a multidisciplinary team of more than 30 top-level specialists and cutting-edge technological equipment such as PET-CT, intraoperative radiotherapy (Mobetron), Personalized Pharmacotherapy, Genetic Counsel or the White Room for to carry out vaccines against cancer, which has made it an international benchmark for the diagnosis and treatment of cancer, to which patients from Spain and Europe go. For years, the Chair of Multidisciplinary Oncology of the UCAM and the Chirónsalud Torrevieja, have worked together to develop research that has subsequently been transferred to practice in the Hospital. Among other techniques, in the so-called HIPEC, which consists in the administration of chemotherapy inside the abdomen with hyperthermia, during surgery. Technique that has been applied for more than fifteen years by the Oncology Platform in the Hospital Quironsalud Torrevieja, and that has recently been adopted by most of the major hospitals in Spain. After many years of studies and advances, it has been shown to be effective in 30% of patients with peritoneal carcinomatosis. Currently it is already accepted by the scientific community as the best alternative for incurable peritoneal metastasis of ovarian or colon cancer.

Source: Quirónsalud Torrevieja y Murcia
Labels: Quirónsalud | oncology | UCAM